PRESS RELEASE published on 05/02/2023 at 18:00, 1 year 4 months ago Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
PRESS RELEASE published on 04/28/2023 at 19:00, 1 year 5 months ago Abivax postpones the publication of its 2023 Universal Registration Document
PRESS RELEASE published on 04/19/2023 at 21:00, 1 year 5 months ago Abivax reports 2022 financial results and operations update
PRESS RELEASE published on 04/18/2023 at 18:00, 1 year 5 months ago Abivax appoints Michael Ferguson as Chief Commerical Officer
PRESS RELEASE published on 04/17/2023 at 18:00, 1 year 5 months ago Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
PRESS RELEASE published on 04/05/2023 at 19:30, 1 year 5 months ago Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
PRESS RELEASE published on 03/16/2023 at 18:30, 1 year 6 months ago Abivax adjusts its 2023 Financial Communication Calendar
PRESS RELEASE published on 03/13/2023 at 12:00, 1 year 6 months ago Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
PRESS RELEASE published on 02/23/2023 at 20:00, 1 year 7 months ago Abivax publishes a prospectus in the context of its capital increase
PRESS RELEASE published on 02/22/2023 at 18:05, 1 year 7 months ago Abivax announces successful oversubscribed EUR 130M cross-over financing at market price with top-tier US and European biotech investors
Published on 09/28/2024 at 02:06, 23 hours 13 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 23 hours 19 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 23 hours 19 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 1 hour ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 11 hours 18 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 2 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 3 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 6 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 6 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 7 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 7 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 7 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 7 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024